The University of Southampton
University of Southampton Institutional Repository

Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus

Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus
Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus

BACKGROUND: Human growth factors are potential therapeutic agents for various inflammatory disorders affecting the gastrointestinal tract. However, they are unstable when administered orally and systemic administration requires high doses increasing the risk of unwanted side effects. Live microorganism-based delivery systems can overcome these problems although they suffer from the inability to control heterologous protein production and there are concerns regarding biosafety and environmental contamination.

METHODS: To overcome these limitations we have developed a new live bacteria drug-delivery system using the human commensal gut bacterium Bacteroides ovatus engineered to secrete human growth factors in response to dietary xylan. The anaerobic nature of B ovatus provides an inherent biosafety feature. B ovatus strains expressing human keratinocyte growth factor-2, which plays a central role in intestinal epithelial homeostasis and repair (BO-KGF), were generated by homologous recombination and evaluated using the dextran sodium sulfate (DSS)-induced model of intestinal epithelial injury and colitis.

RESULTS: In response to xylan BO-KGF produced biologically active KGF both in vitro and in vivo. In DSS treated mice administration of xylan and BO-KGF had a significant therapeutic effect in reducing weight loss, improving stool consistency, reducing rectal bleeding, accelerating healing of damaged epithelium, reducing inflammation and neutrophil infiltration, reducing expression of pro-inflammatory cytokines, and accelerating production of goblet cells. BO-KGF and xylan treatment also had a marked prophylactic effect limiting the development of inflammation and disruption of the epithelial barrier.

CONCLUSION: This novel, diet-regulated, live bacterial drug delivery system may be applicable to treating various bowel disorders.

Animals, Bacteroides/drug effects, Biological Assay/methods, Cell Proliferation/drug effects, Colitis/chemically induced, Dextran Sulfate, Disease Models, Animal, Drug Delivery Systems/methods, Endo-1,4-beta Xylanases/genetics, Fibroblast Growth Factor 10/administration & dosage, Genetic Engineering/methods, Intestinal Mucosa/drug effects, Male, Mice, Mice, Inbred C57BL, Mucins/biosynthesis, Promoter Regions, Genetic, Xylans/pharmacology
1468-3288
461-469
Hamady, Zaed Z R
545a1c81-276e-4341-a420-aa10aa5d8ca8
Scott, Nigel
d9f917a3-afb5-47e2-81da-5149c0420c82
Farrar, Mark D
5b6b2aad-3bb6-400f-9ae3-cb8f9be8cd57
Lodge, J Peter A
c97dd104-0cb2-4f05-a008-9b9af01e4820
Holland, Keith T
59cafad5-1008-4848-aef6-bc9b0a249839
Whitehead, Terence
6d7a75b8-215f-4602-afba-07c97be26ba4
Carding, Simon R
1104c711-b95b-4ed5-9cc6-6d09f1f268ea
Hamady, Zaed Z R
545a1c81-276e-4341-a420-aa10aa5d8ca8
Scott, Nigel
d9f917a3-afb5-47e2-81da-5149c0420c82
Farrar, Mark D
5b6b2aad-3bb6-400f-9ae3-cb8f9be8cd57
Lodge, J Peter A
c97dd104-0cb2-4f05-a008-9b9af01e4820
Holland, Keith T
59cafad5-1008-4848-aef6-bc9b0a249839
Whitehead, Terence
6d7a75b8-215f-4602-afba-07c97be26ba4
Carding, Simon R
1104c711-b95b-4ed5-9cc6-6d09f1f268ea

Hamady, Zaed Z R, Scott, Nigel, Farrar, Mark D, Lodge, J Peter A, Holland, Keith T, Whitehead, Terence and Carding, Simon R (2010) Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut, 59 (4), 461-469. (doi:10.1136/gut.2008.176131).

Record type: Article

Abstract

BACKGROUND: Human growth factors are potential therapeutic agents for various inflammatory disorders affecting the gastrointestinal tract. However, they are unstable when administered orally and systemic administration requires high doses increasing the risk of unwanted side effects. Live microorganism-based delivery systems can overcome these problems although they suffer from the inability to control heterologous protein production and there are concerns regarding biosafety and environmental contamination.

METHODS: To overcome these limitations we have developed a new live bacteria drug-delivery system using the human commensal gut bacterium Bacteroides ovatus engineered to secrete human growth factors in response to dietary xylan. The anaerobic nature of B ovatus provides an inherent biosafety feature. B ovatus strains expressing human keratinocyte growth factor-2, which plays a central role in intestinal epithelial homeostasis and repair (BO-KGF), were generated by homologous recombination and evaluated using the dextran sodium sulfate (DSS)-induced model of intestinal epithelial injury and colitis.

RESULTS: In response to xylan BO-KGF produced biologically active KGF both in vitro and in vivo. In DSS treated mice administration of xylan and BO-KGF had a significant therapeutic effect in reducing weight loss, improving stool consistency, reducing rectal bleeding, accelerating healing of damaged epithelium, reducing inflammation and neutrophil infiltration, reducing expression of pro-inflammatory cytokines, and accelerating production of goblet cells. BO-KGF and xylan treatment also had a marked prophylactic effect limiting the development of inflammation and disruption of the epithelial barrier.

CONCLUSION: This novel, diet-regulated, live bacterial drug delivery system may be applicable to treating various bowel disorders.

This record has no associated files available for download.

More information

e-pub ahead of print date: 7 September 2009
Published date: 23 March 2010
Additional Information: © 2009, Published by the BMJ Publishing Group Limited
Keywords: Animals, Bacteroides/drug effects, Biological Assay/methods, Cell Proliferation/drug effects, Colitis/chemically induced, Dextran Sulfate, Disease Models, Animal, Drug Delivery Systems/methods, Endo-1,4-beta Xylanases/genetics, Fibroblast Growth Factor 10/administration & dosage, Genetic Engineering/methods, Intestinal Mucosa/drug effects, Male, Mice, Mice, Inbred C57BL, Mucins/biosynthesis, Promoter Regions, Genetic, Xylans/pharmacology

Identifiers

Local EPrints ID: 457902
URI: http://eprints.soton.ac.uk/id/eprint/457902
ISSN: 1468-3288
PURE UUID: 3d3802ee-910f-418c-80ca-3abab7c48212
ORCID for Zaed Z R Hamady: ORCID iD orcid.org/0000-0002-4591-5226

Catalogue record

Date deposited: 21 Jun 2022 18:17
Last modified: 17 Mar 2024 04:12

Export record

Altmetrics

Contributors

Author: Zaed Z R Hamady ORCID iD
Author: Nigel Scott
Author: Mark D Farrar
Author: J Peter A Lodge
Author: Keith T Holland
Author: Terence Whitehead
Author: Simon R Carding

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×